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Background: Release and dispersion of particles arising from corrosion and wear of total hip arthroplasty (THA) components has
raised concerns about a possible increased risk of cancer. Concerns have been heightened by a recent revival in the use of metal-
on-metal (MoM) hip prostheses.
Methods: From a linked database of hospital discharge, cancer registration, and mortality records, we selected a cohort of
patients who underwent primary THA (1990–2009) or primary resurfacing arthroplasty (mainly 2000–2009) in Scotland, with follow-
up to the end of 2010. Available operation codes did not enable us to distinguish MoM THAs. Indirectly standardised incidence
ratios (SIRs) were calculated for selected cancers with standardisation for age, sex, deprivation, and calendar period.
Results: The study cohort included 71 990 patients yielding 547 001 person-years at risk (PYAR) and 13 946 cancers diagnosed
during follow-up. For the total period of observation combined, the risks of all cancers (SIR: 1.05; 95% CI: confidence interval 1.04–
1.07), prostate cancer (SIR: 1.07; 95% CI: 1.01–1.14), and multiple myeloma (SIR: 1.22; 95% CI: 1.06–1.41) were increased. These
modest increases in risk emerged in the context of effectively multiple tests of statistical significance, and may reflect inadequate
adjustment for confounding factors. For 1317 patients undergoing primary resurfacing arthroplasty between 2000 and 2009
(PYAR¼ 5698), the SIR for all cancers (n¼ 39) was 1.23 (95% CI: 0.87–1.68).
Conclusion: In the context of previous research, these results do not suggest a major cause for concern. However, the duration of
follow-up of patients receiving recently introduced, new-generation MoM prostheses is too short to rule out a genuinely increased
risk of cancer entirely.
Since the earliest recorded attempts at hip replacement surgery
more than 100 years ago (Knight et al, 2011), millions of patients
have undergone total hip arthroplasty (THA) worldwide (Polyzois
et al, 2012). A variety of materials have been used for the bearing
surfaces of hip prostheses, the principal modern options being
metal-on-polyethylene, metal-on-metal, ceramic-on-polyethylene,
and ceramic-on-ceramic. Systemic exposure to chromium, cobalt,
nickel, and aluminium alloys can occur because of the formation of
metal wear nanoparticles that are released both from metal-on-
metal and metal-on-polyethylene bearings, resulting in a post-
operative increase in metal ion levels at different organ sites,
especially those comprising the lymphoreticular system. These
particles circulate locally and systemically, penetrate cell plasma
membranes, bind to cellular proteins and enzymes, cause
chromosome aberrations and DNA damage, modulate cytokine
expression, and might, therefore, cause long-term increased risks of
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cancer (Visuri et al, 2010; Ma¨kela¨ et al, 2012; Polyzois et al, 2012).
Although a Working Group established by the International
Agency for Research on Cancer concluded that there is inadequate
evidence in humans for the carcinogenicity of metallic implants,
metallic foreign bodies, and orthopaedic implants of complex
composition (IARC Monographs on the Evaluation of
Carcinogenic Risks to Humans, 1999), this finding does not rule
out a risk of cancer entirely, and the evidence reviewed pre-dated
the emergence of the modern generation of metal-on-metal hip
prostheses (Cohen, 2011).
Two early cohort studies of cancer risk following THA found an
increased risk of lymphohaematopoietic malignancies (Gillespie
et al, 1988; Visuri and Koskenvuo, 1991), but apart from an excess
of multiple myeloma emerging during long-term follow-up
(Signorello et al, 2001), other studies (Mathiesen et al, 1995;
Nyre´n et al, 1995; Gillespie et al, 1996; Visuri et al, 1996, 2010;
Olsen et al, 1999; Paavolainen et al, 1999; Goldacre et al, 2005;
Ma¨kela¨ et al, 2012) have not shown an excess risk of these cancers.
However, some other studies have reported excess risks of
melanoma of the skin (Nyre´n et al, 1995; Olsen et al, 1999;
Signorello et al, 2001; Ma¨kela¨ et al, 2012), prostate cancer (Nyre´n
et al, 1995; Signorello et al, 2001), kidney cancer (Nyre´n et al,
1995), and basal cell carcinoma of the skin, specifically in patients
with modern generation metal-on-metal hip replacements
(Ma¨kela¨ et al, 2012). Although there have been case reports of
bone and soft tissue sarcomas arising adjacent to orthopaedic
implants (IARC Monographs on the Evaluation of Carcinogenic
Risks to Humans, 1999; Vahey et al, 1995), none of the cohort
studies so far conducted have demonstrated a statistically
significant excess risk of these kinds of cancers. Recent meta-
analyses and reviews of studies of cancer risk following THA (as
well as, in some cases, total knee arthroplasty) have also identified
increased risks of skin melanoma (Visuri et al, 2003, 2006;
Onega et al, 2006), prostate cancer (Visuri et al, 2003, 2006; Onega
et al, 2006), cancer of the endometrium (Visuri et al, 2003),
and cancers of the urinary tract and mouth/pharynx (Onega et al,
2006). More recently, a record linkage study between the
National Joint Registry of England and hospital episode statistics
did not find any evidence of an association between metal-on-
metal hip replacements and increased risk of admission to
hospital with cancer in the first 7 years after hip replacement
(Smith et al, 2012).
Recent concerns and publicity about a possible association
between the new generation of metal-on-metal hip joint
replacement devices and subsequent risk of cancer prompted us
to investigate the risk of cancer among patients treated with
THA or primary resurfacing arthroplasty of the hip in
Scotland (estimated total mid-year population approximately
5.25 million in 2011).
MATERIALS AND METHODS
Study population. The study population was drawn from the
permanently linked database of acute hospital discharges, cancer
registrations, and mortality records in Scotland (Kendrick and
Clarke, 1993). From National Health Service (NHS) acute
hospital discharge records, we selected patients undergoing
primary total hip replacement or primary resurfacing arthroplasty
of the hip during the period 1990–2009 inclusive, based on the
following OPCS-4 procedure codes (Office of Population Censuses
and Surveys, 1990):
 W37.1: Primary total prosthetic replacement of hip joint using
cement.
 W38.1: Primary total prosthetic replacement of hip joint not
using cement.
 W39.1: Primary total prosthetic replacement of hip joint NEC.
 W58.1þZ84.3: Primary resurfacing arthroplasty of jointþ hip
joint.
These OPCS-4 codes include, but are not specific to, metal-on-
metal hip replacements, which, in common with the rest of the
world, increased in use in Scotland between 2005 and 2009. For
example, it is not possible to distinguish large diameter head metal-
on-metal total hip replacements.
Each member of the study cohort was followed up for cancer
incidence from the date of their earliest relevant hip surgery until
death or the end of 2010 (whichever occurred first). As in other
recent studies (Visuri et al, 2010; Ma¨kela¨ et al, 2012), follow-up was
not censored at the date of diagnosis of first cancer; all primary
cancers diagnosed during the follow-up period were counted as
observed cases. Cancers occurring before each patient’s hip
operation were disregarded.
Statistical methods. Indirectly standardised incidence ratios
(SIRs) were calculated for selected cancers based on the ratio of
observed to expected numbers of cancers. The list of cancers
investigated (Appendix 1) was determined before analysis, and was
based on excess risks of specific cancers reported from previous
studies, as well as a list of cancers identified in an unpublished
study from Wales, which had been a source of concern. Expected
numbers of cancers were calculated by applying national age-, sex-,
deprivation category-, and calendar period-specific (and cancer-
specific) rates to the age-, sex-, deprivation category-, and calendar
period-specific person-years at risk (PYAR) in the study cohort.
Rates were calculated using population denominator data sourced
from the General Register Office for Scotland (now part of
National Records of Scotland). The Scottish Index of Multiple
Deprivation (SIMD) 2004 (Scottish Government, 2004) was used
as a postcode-referenced, small area indicator of socioeconomic
position. This has seven domains (income, employment, education,
housing, health, crime, and geographical access) at ‘datazone’ level
(areas with approximately 500–1000 household residents), which
have been combined into an overall index to identify area
concentrations of multiple deprivation. SIMD population
estimates are only available from 1996 onwards, so we used 1996
estimates for the period 1990–1995. We calculated 95% confidence
intervals (CIs) for SIRs by assuming that the observed numbers of
cancers follow a Poisson distribution. SIRs with 95% CIs that did
not include the value 1.00 were regarded as statistically significant.
SIRs were calculated for the total period of observation, and also
partitioned by a period of hip surgery (1990–1994, 1995–1999,
2000–2004, and 2005–2009), and by time since hip operation (o1
year, 1–4 years, 5–9 years, and X10 years). In addition, we
performed a subgroup analysis of patients recorded as undergoing
primary resurfacing arthroplasty during 2000–2009.
RESULTS
The distribution and characteristics of the study population are
summarised in Table 1. Overall, the study cohort included 71 990
patients yielding 547 001 PYAR. The female-to-male ratio was
1.6:1.0, and almost 80% of patients were aged 60 years or older at
the time of their first relevant hip surgery. Higher proportions of
patients were from the second and third least deprived fifths of
SIMD 2004, whereas lower proportions were from the least and
(especially) the most deprived fifth. The overwhelming majority of
patients (498% in both sexes combined) were recorded as having
primary total hip replacement rather than primary resurfacing
arthroplasty as their first relevant procedure. More than 99%
(1317 out of 1325) of primary resurfacing arthroplasties were
performed during 2000–2009. In both sexes combined, the mean
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age at study entry was 68 years and the mean number of years of
follow-up was 7.6. During follow-up, 13 946 cancers were
diagnosed in the whole study cohort and the mean age at diagnosis
of cancer was 76.1 years.
Table 2 shows the observed numbers of cancers, SIRs, and 95%
CIs, by calendar period of hip operation. Standardised incidence
ratios were significantly higher than expected for cutaneous
melanoma and for basal cell carcinoma of the skin among patients
operated on during 2005–2009 (SIR: 1.42; 95% CI: 1.07–1.86 and
SIR: 1.12; 95% 1.01–1.24, respectively); for prostate cancer among
patients operated on during 1990–2009 (SIR: 1.07; 95% CI: 1.01–
1.14); for multiple myeloma and other immunoproliferative
neoplasms among patients operated on during 1995–1999 (SIR:
1.43; 95% CI: 1.13–1.80) and 1990–2009 (SIR: 1.22; 95% CI: 1.06–
1.41); and for all cancers combined among patients operated on
during 1995–1999 (SIR: 1.07; 95% CI: 1.04–1.10), 2000–2004 (SIR:
1.04; 95% CI: 1.00–1.08), 2005–2009 (SIR: 1.13; 95% CI: 1.09–
1.18), and 1990–2009 (SIR: 1.05; 95% CI: 1.04–1.07). Significantly
low SIRs were observed for lung cancer during every calendar
period and for cancers of the upper gastrointestinal tract and
bladder during the whole study period combined.
Table 3 shows the observed numbers of cancers, SIRs, and 95%
CIs, by time since hip operation. A significant excess of basal cell
carcinoma of the skin (SIR: 1.11; 95% CI: 1.04–1.18), multiple
myeloma and other immunoproliferative neoplasms (SIR: 1.37;
95% CI: 1.09–1.70), and all cancers combined (SIR: 1.10; 95% CI:
1.07–1.13) occurred during the interval 1–4 years following
primary hip surgery. Significantly low SIRs were observed for
lung cancer during every follow-up interval, for cancers of the
oesophagus during the interval 5–9 years after surgery, and for
bladder cancer within a year of surgery or 10 years or more after
surgery.
In the subgroup analysis of 1317 patients recorded as under-
going primary resurfacing arthroplasty between 2000 and 2009,
during 5698 PYAR, 39 cancers were observed (SIR: 1.23; 95% CI:
0.87–1.68). These included 10 prostate cancers (SIR: 1.89;
95% CI: 0.90–3.50), six basal cell carcinomas of the skin (SIR:
0.62; 95% CI: 0.22–1.36), one cutaneous melanoma (SIR: 0.62;
95% CI: 0.00–3.56), and no myelomas. Between zero and two cases
were observed for remaining cancer sites/types, and no SIRs were
significantly different from 1.00 in this subgroup of patients.
DISCUSSION
Although our results imply an overall excess risk of cancer of 5%
(SIR: 1.05) associated with prior hip arthroplasty, this seems
unlikely to be of aetiological or clinical significance. Standardised
incidence ratios of a similar order of magnitude (although not
quite statistically significant) have been reported previously from a
Swedish study (SIR: 1.03; 95% CI: 1.00–1.06) and for a non-metal-
on-metal hip replacement cohort from Finland (SIR: 1.04; 95% CI:
0.99–1.09) (Nyre´n et al, 1995; Ma¨kela¨ et al, 2012). However, the
majority of studies have reported lower than expected risks of
cancer overall following hip replacement surgery (Olsen et al, 1999;
Paavolainen et al, 1999; Visuri et al, 2003, 2010; Onega et al, 2006;
Smith et al, 2012). It has been speculated that this may reflect a
‘healthy patient effect’ since patients have to have a certain level of
Table 1. Distribution and summary characteristics of the study population
Males Females Persons
Number % Number % Number %
Age group (years)
o40 637 2.3 730 1.7 1367 1.9
40–49 1469 5.3 1651 3.7 3120 4.3
50–59 4960 17.8 5955 13.5 10 915 15.2
60–69 9575 34.4 13 434 30.4 23 009 32.0
70–79 8656 31.1 15 723 35.6 24 379 33.9
X80 2501 9.0 6699 15.2 9200 12.8
Deprivation fifth
1 – Least deprived 5277 19.0 8137 18.4 13 414 18.6
2 6474 23.3 9496 21.5 15 970 22.2
3 6566 23.6 10 118 22.9 16 684 23.2
4 5413 19.5 9178 20.8 14 591 20.3
5 – Most deprived 4068 14.6 7263 16.4 11 331 15.7
Type of surgery
Primary total hip replacement 26 909 96.8 43 756 99.0 70 665 98.2
Primary resurfacing arthroplasty 889 3.2 436 1.0 1325 1.8
Total 27 798 100 44192 100 71990 100
Mean age at study entry (years) 66.3 69.1 68.0
Median calendar year at study entry 2001 2001 2001
Mean number of years of follow-up 7.5 7.7 7.6
Person-years at risk 208 001 338 999 547 001
Number of cancers diagnosed during
follow-up
6253 7693 13 ,946
Mean age at diagnosis of cancer 75.2 76.7 76.1
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fitness to tolerate major surgery (Paavolainen et al, 1999; Ma¨kela¨
et al, 2012; Smith et al, 2012). It might equally reflect higher than
average lifetime levels of physical activity (and therefore injury)
among some patients presenting with osteoarthritis of the hip,
which would tend to reduce the risk of certain cancers (World
Cancer Research Fund/American Institute for Cancer Research,
2007). Alternatively, it could reflect the use of medication, such as
non-steroidal anti-inflammatory agents, which may also reduce the
risk of some cancers (Olsen et al, 1999; Paavolainen et al, 1999).
It is important to note that our study population was not evenly
distributed across the deprivation fifths, with a much lower
proportion than expected in the most deprived fifth (Table 1).
Although our efforts to standardise our results for socioeconomic
position may have succeeded in attenuating any ‘healthy patient
effect’, it must be acknowledged that our use of the SIMD 2004
indicator (Scottish Government, 2004), based on the area of
residence and imperfect population estimates (see Materials and
Methods), is very unlikely to have eliminated all confounding
related to this factor. As noted above, it is probable that recipients
of hip replacements also differ systematically from the general
population in other respects, such as lifestyle factors and
medication history, which may determine their risk of developing
cancer. We have not been able to make any adjustment for these
factors, which may represent additional sources of confounding.
Some previous studies have excluded patients with rheumatoid
arthritis at baseline on the grounds that they have a non-typical
pattern of cancer (Visuri et al, 1996, 2010; Olsen et al, 1999;
Paavolainen et al, 1999; Ma¨kela¨ et al, 2012). We did not feel that
this was appropriate in our study because a previous study of
hospitalised patients with rheumatic diseases in Scotland suggested
even more atypical patterns of cancer risk among patients with
osteoarthritis: SIRs for all cancers (excluding non-melanoma skin
cancer) in patients with rheumatoid arthritis were 1.11 (95% CI:
1.03–1.21) in male patients and 0.96 (95% CI: 0.90–1.01) in female
patients; and in patients with osteoarthritis 0.85 (95% CI: 0.81–
0.88) in male patients and 0.83 (95% CI: 0.80–0.86) in female
patients (Thomas et al, 2000). The proportion of patients with
rheumatoid arthritis (when this has been reported) in previous
cohorts of hip replacement patients has typically been low. For
example, in a previous study including Scottish patients, only 12%
of the THA cohort had a main diagnosis of rheumatoid arthritis,
and adjustment for this in a statistical model did not change the
relative risk of leukaemia/lymphoma significantly (Gillespie et al,
1996).
Theoretically, using hospital discharge records, it would also be
possible to allow for co-morbid conditions recorded during
hospitalisation that have been associated with altered risks of
cancer, such as diabetes mellitus (Giovannucci et al, 2010).
However, we did not attempt this because, in Scotland at least,
there is some evidence of under-recording of comorbid conditions
in hospital discharge data (Anwar et al, 2011).
The consistent finding of a lower risk of lung cancer in our
cohort has been reported in previous studies (Mathiesen et al,
1995; Visuri et al, 1996, 2003, 2010; Paavolainen et al, 1999;
Goldacre et al, 2005; Onega et al, 2006; Ma¨kela¨ et al, 2012) and
may reflect a lower prevalence of smoking among patients regarded
as fit for surgery, or that patients with a history of smoking have
been advised to give up before surgery. At the same time, however,
there is some evidence that the risk of severe osteoarthritis of the
hip may be lower in smokers, at least as far as men are concerned
(Visuri et al, 2010). These potential explanations might also
account for the deficits we observed in other smoking-related
cancers (upper gastrointestinal tract and bladder).
Some other studies have reported excess risks of melanoma of
the skin (Nyre´n et al, 1995; Olsen et al, 1999; Signorello et al, 2001;
Visuri et al, 2003, 2006; Onega et al, 2006; Ma¨kela¨ et al, 2012),
basal cell carcinoma of the skin (specifically in patients with
modern generation metal-on-metal hip replacements) (Ma¨kela¨
et al, 2012), and prostate cancer (Nyre´n et al, 1995; Signorello et al,
2001). Although the recent UK study (Smith et al, 2012) had the
major advantage of being able to focus on metal-on-metal hip
replacements by using the National Joint Registry of England to
ascertain exposure, their assessment of outcome was based on
linkage to hospital episode statistics, which are subject to less
quality assurance than cancer registry data, and are likely to be
missing information on some cancers, such as cutaneous
melanoma, that do not necessarily lead to hospital admission. It
has been speculated that the excess risk of melanoma reported in
several studies could be due to surveillance bias (Olsen et al, 1999),
although we did not observe a significantly increased risk during
earlier follow-up intervals. All major types of skin cancer (Doherty
et al, 2010) and prostate cancer (Shafique et al, 2012) are
considerably more common among more affluent individuals, so
the increased risks of these cancers observed in our study could
reflect residual confounding by socioeconomic position. However,
in contrast to the recent Finnish study of patients with modern
generation metal-on-metal hip replacements (Ma¨kela¨ et al, 2012),
our subgroup analysis of patients undergoing primary resurfacing
arthroplasty (although based on relatively small numbers) did not
show an increased risk of basal cell carcinoma of the skin.
An increased risk of multiple myeloma has been reported in one
previous study (Signorello et al, 2001), but this only emerged
during long-term follow-up (X15 years), which is not really
consistent with our findings, and was of borderline statistical
significance (SIR 1.86; 95% CI: 1.01–3.11). Like skin cancer,
myeloma may also be susceptible to surveillance bias, related to
routine blood testing and X-rays in patients with rheumatic
conditions, especially those undergoing surgery. Modestly elevated
risks of myeloma have been reported in some (but not all) studies
of patients with rheumatoid arthritis as well as some other
autoimmune diseases and chronic inflammatory conditions, and
some studies have found positive but nonsignificant associations
between use of anti-inflammatory medications and myeloma
(De Roos et al, 2006). However, none of these associations are
entirely consistent or convincing. The majority of studies (Nyre´n
et al, 1995; Visuri et al, 1996, 2003, 2006, 2010; Olsen et al, 1999;
Paavolainen et al, 1999; Goldacre et al, 2005; Onega et al, 2006;
Ma¨kela¨ et al, 2012) have not shown an increased risk of this
malignancy following hip replacement surgery.
Our study has a number of strengths. Hospitalisation data are
supported by an active programme of quality assurance including
regular assessments of data quality. In relation to discharges from
acute hospitals, the accuracy of coding of main operation/
procedure has been estimated to be around 94% overall and has
been relatively stable for around 20 years (Information Services
Division, 2012). In particular, the coding of arthroplasty
procedures is quality assured in the context of the Scottish
Arthroplasty Project (2012), which was established in 1999.
Scottish Cancer Registry data have also been shown to be of
comparatively high quality (Brewster et al, 1997, 2002), and record
linkage in Scotland is believed to be highly accurate and complete
(Kendrick and Clarke, 1993).
The main weakness of our study is that, in the absence of a joint
register in Scotland, we were unable to assess the risk of cancer
separately for all metal-on-metal arthroplasties. Thus, we have only
been able to infer the predominant types of prostheses in use based
on the era of surgery and local specialist knowledge. Over 4000
patients in receipt of modern generation metal-on-metal pros-
theses have been identified in a survey of NHS Boards in Scotland
(Scottish Government, 2012). However, this represents a relatively
small proportion of all patients undergoing hip arthroplasty, and
suggests that Scottish orthopaedic surgeons may not have adopted
these new generation prostheses with the same enthusiasm as some
of their peers in other countries.
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Patients who had their hip surgery in the private sector, not
funded by the NHS, are unlikely to be included in acute NHS
hospital discharge data, although in Scotland, it is estimated that
the majority (well over 90%) of these procedures are carried out in,
or at least funded by, the NHS. Although the linked database in
Scotland extends back to 1981, procedure coding is less precise and
may have been less accurate in the 1980s. For this reason, we
restricted our study to patients operated on from 1990 onwards,
meaning that long-term follow-up is somewhat limited, especially
for the cohort operated on most recently who are more likely to
have received metal-on-metal prostheses. Although we were
concerned that we might have overestimated risks by including
cases diagnosed in the first year of follow-up, there is little evidence
of surveillance bias in our results. Partitioning our analyses by
cancer type, period of surgery, and interval of follow-up has
inevitably resulted in multiple testing, which increases the risk of a
type I error (rejection of a true null hypothesis). At the same time,
however, we had limited statistical power to detect altered risks of
cancer in our subgroup analysis of patients who had undergone
primary resurfacing arthroplasty.
In conclusion, although we observed an increased risk of all
cancers combined in our cohort, this was small in magnitude and
could easily be the result of confounding. We found no statistically
significant evidence of an increased risk of cancer after long-term
(X10 years) follow-up, no evidence of increased risks in our
subgroup analysis of patients who underwent primary resurfacing
arthroplasty, and for specific types of cancer, no consistent pattern
of increased risk across all calendar periods of surgery or intervals
of follow-up. The accumulated body of research on this topic does
not suggest a major cause for concern. However, follow-up of
individuals operated on most recently, who are more likely to have
been exposed to new-generation metal-on-metal prostheses, is
necessarily limited and it will be important to re-assess the risk of
cancer among this group after a further period of follow-up has
accrued. Discussions are currently taking place about the feasibility
of developing a joint replacement register in Scotland, which in
future would provide the possibility of examining cancer risk by
type of prosthesis, thereby addressing one of the main limitations
of this study.
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APPENDIX 1
Table 1. Cancers investigated in the study, and their diagnostic codes
according to the ninth (ICD-9) and tenth (ICD-10) revisions of the
International Classification of Diseases
Cancer ICD-9 ICD-10
Mouth, pharynx 141, 143–149 C01–C06,
C09–C14
Oesophagus 150 C15
Stomach 151 C16
Lung 162 C33, C34
Bone 170 C40, C41
Connective tissue 171 C47, C49
Melanoma of skin 172 C43
Basal cell carcinoma of skin 173, ICD-O
M-809
C44, ICD-O
M-809
Table 1. ( Continued )
Corpus uteri 182 C54
Prostate 185 C61
Bladder* 188, 233.7, 236.7,
239.4
C67, D09.0,
D41.4
Kidney 189 C64, C65
Hodgkin’s disease 201 C81
NHL and other lymphohaemato-
poietic
200, 202.0–202.3,
202.5–202.8
C82–C85, C96
Multiple myeloma and other
immunoproliferative
203 C88, C90
Leukaemia 202.4, 204–208 C91–C95
All cancers combined 140–208 C00–C96
*Because of changes in classification and coding of bladder tumours over time, all bladder
tumours (invasive, in situ, and uncertain behaviour) were included.
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